Heidi Evidence Is Excellent. UK NHS Clinicians Are Excluded.

Heidi Evidence is the most strategically interesting clinical AI tool to land in 2026. It is free for individual clinicians. It is citation-backed. It is partnered with NICE, BMJ Group, MIMS and HealthPathways — the four most credible UK clinical-content sources a tool in this space could pair with. We have read the output carefully. It is good.

UK NHS clinicians cannot use it.

Heidi Evidence enrolment blocks email addresses on the major NHS domains. Try signing up with an nhs.net, nhs.uk, NHS Wales, NHS Scotland or HSC Northern Ireland address and you do not get in. Australian, US and Singapore clinicians can sign up. UK NHS staff cannot.

This is the third UK AI exclusion in six weeks. We think it matters.

What Heidi Evidence actually does

Heidi Evidence is a clinical decision support tool. You ask a clinical question — the kind of question you might have asked a colleague on the way to coffee — and it returns a synthesised answer with citations you can click through to.

The synthesis is grounded in named, recognisable UK sources. The NICE partnership means guidelines come from where they should come from. The BMJ Group content gives the answers a familiar editorial register. MIMS gives prescribing detail. HealthPathways adds local-pathway awareness for the regions where it is deployed.

Two things make Heidi Evidence stand out from earlier clinical AI tools.

The first is that the citations are honest. Click any reference and you land on the source — NICE guideline, BMJ article, MIMS entry — exactly as quoted. This is not always true of clinical AI tools, and it has been a real problem with some of the larger-funded US entries.

The second is that there is no advertising and no sponsored content. The product is free at the individual tier and the funding model does not depend on shaping which answers surface.

For UK NHS clinicians, the catch is that none of this matters yet. The sign-up page does not let you in.

What "excluded" actually looks like

The block is at enrolment, not at access. There is no message saying "Heidi Evidence will arrive in the UK on…". There is no waitlist. There is no UK regional page with a release timeline.

If you try to sign up with a UK NHS email, the enrolment flow rejects the domain. If you try a personal Gmail or Outlook address, you can register — but the product is plainly intended for verified clinicians and the workflow is engineered around clinician-domain emails. UK NHS staff are not the target user.

Heidi Scribe — the AI clinical scribe that drafts consultation notes — is a different story. Heidi Scribe is separately MHRA-cleared and remains available to UK clinicians, including NHS staff. If you have been using Heidi Scribe, you keep that. The exclusion is specific to Heidi Evidence.

Why the exclusion is happening

Heidi Health has not publicly explained the UK NHS block. The most likely explanation is regulatory.

Heidi Evidence generates AI-synthesised clinical recommendations from a clinical query. Under MHRA classification, that is the kind of output that pushes a tool toward Software as a Medical Device territory. The NICE, BMJ Group, MIMS and HealthPathways partnerships are content arrangements — they describe what the model is grounded in, not how the model is classified.

The UK regulatory framework for AI in healthcare is mid-flight. The Medical Devices (Amendment) Regulations consultation closes 19 June 2026. The International Reliance Framework is planned for Autumn 2026. The National Commission on AI in Healthcare report is due later in the year. Until these land, an internationally launched clinical AI product that operates fine in Australia, the US and Singapore is unlikely to risk UK NHS deployment.

This is the same logic that took OpenEvidence out of the UK on 28 April 2026 and the same logic that has kept ChatGPT for Clinicians US-first since 23 April. None of these companies has cited the UK as a strategic concern. The UK has been deferred while the rules are being written.

The pattern UK clinicians should be aware of

In the space of six weeks, three clinical AI tools in the same category have stepped back from the UK:

• 23 April 2026: ChatGPT for Clinicians launches. UK and EEA excluded at the verification step.
• 28 April 2026: OpenEvidence withdraws from the UK and EU.
• May 2026: Heidi Evidence confirmed blocking UK NHS email addresses at enrolment.

All three offered the same broad use case — point-of-care clinical Q&A grounded in cited sources. UK doctors have lost three credible options for that job in less than two months.

We have written separately about the OpenEvidence withdrawal and the ChatGPT for Clinicians exclusion. Heidi Evidence is the third post in what is now a clear sequence.

What is striking is that Heidi Evidence — unlike the other two — is the one product that did everything right on the UK content side. NICE partnership. BMJ Group partnership. UK-relevant prescribing data. And it still cannot be used by NHS staff. That is the regulatory environment talking, not the product.

What UK clinicians can use right now

For clinical Q&A at the point of care: iatroX is the UK-based option. It holds MHRA registration as a Class I device, carries UKCA marking, and is built around UK guideline retrieval (NICE, CKS, SmPC) with calculators and Q-banks attached. It is not a perfect substitute for Heidi Evidence's model quality, but it is the most credible UK-regulatory-compliant tool in this space today.

For AI clinical documentation: Heidi Scribe remains available and MHRA-cleared. If you have not yet looked at clinical scribe tools and you write a lot of consultation notes, this is worth your time.

For staying current with the medical literature — knowing what was published in your specialty each week — that is a different job altogether. Q&A tools answer questions you have already thought to ask. They cannot tell you about the practice-changing trial that landed last Tuesday. That is the gap The Monday Clinical Brief is built to close.

We have written more on how Heidi Evidence and a weekly digest fit together when both are available. For UK NHS clinicians, only one of the two is currently usable.

A short note on Claude

Heidi Evidence is powered in part by Anthropic Claude. So is The Monday Clinical Brief — we use Claude to summarise the weekly journal output for each of our 31 specialties. We mention this only because it is worth knowing: the underlying model choice is the same. The product around the model is what differs. Heidi Evidence wraps the model in a query interface and clinical-source partnerships. MCB wraps the model in a weekly editorial cadence and a UK clinician's perspective.

What we offer

The Monday Clinical Brief sends one email every Monday morning. In that email are the most important peer-reviewed papers published in your specialty over the previous week — plain-language summaries, links to the originals, and the UK context (NICE, Royal College, NHS pathway) where it matters.

We cover 31 specialties. We are reader-paid at £20 a year. No advertising, no sponsored papers, no regulatory uncertainty — we are not a medical device and we do not claim to be one. We are a weekly reading habit you can log for CPD.

Subscribe to The Monday Clinical Brief — and know what was published last week before any of these AI tools could have told you about it.

The bottom line

Heidi Evidence is excellent. UK NHS clinicians cannot use it yet. This will probably change once the UK regulatory framework for clinical AI lands — but the timeline is months, not weeks.

In the meantime: iatroX for UK clinical Q&A, Heidi Scribe for documentation if you want it, and MCB for keeping current with the literature itself. Each tool does one job well. Together they cover most of what the absent products would have done.

We will update this post when Heidi Evidence becomes available to UK NHS accounts. Evidence suggests that will be after the Medical Devices (Amendment) Regulations consultation closes in June 2026 — but until then, the block is firm.